Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Court filingGlobeNewswire· May 19, 2026

Hagens Berman Files New Securities Class Action Against Super Micro Computer (SMCI) And Its Senior Executives: New Complaint Alleges Additional Corrective Disclosures; Lead Plaintiff Filing Deadline Remains May 26, 2026

View original at globenewswire.com
Hagens Berman Files New Securities Class Action Against Super Micro Computer (SMCI) And Its Senior Executives: New Complaint Alleges Additional Corrective Disclosures; Lead Plaintiff Filing Deadline Remains May 26, 2026 SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Hagens Berman announces that the firm has filed a ne…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Defendants carried out a two-phase campaign of deception: first by making public assurances of compliance with U.S. export restrictions, and second by providing only partial corrective information after the Company missed SEC filing deadlines, EY resigned, and the Special Committee investigation was opened, while continuing to conceal the underlying export fraud

    60% confidence
  • Super Micro co-founder and SVP Yih-Shyan 'Wally' Liaw and others conspired to divert high-performance servers to China, generating at least approximately $2.5 billion in sales, involving staging of 'dummy' servers, fabrication of data center lease agreements, and active obstruction of internal compliance audits

    60% confidence
  • Super Micro's stock continued to trade at artificially inflated prices until the full scope of the fraud was revealed by the Indictment, because neither the August 28 nor October 30, 2024 disclosures revealed the underlying illegal diversion of servers to China

    60% confidence
  • At or around the time EY resigned in October 2024, Liaw and another Super Micro senior employee were actively undermining the Company's compliance audit of Company-1 by preventing auditors from entering facilities, arranging for a 'friendly' auditor, and fabricating lease agreements to create a false appearance of sufficient data center capacity

    60% confidence
  • Super Micro and certain senior officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making false and misleading statements and concealing an illegal scheme to sell billions of dollars' worth of servers embedded with Nvidia AI chips to China through a Southeast Asian passthrough entity

    60% confidence
  • Ernst & Young's resignation was due in part to its concern over at least eleven specific export transactions and the Special Committee's inquiry expressly concerned whether Super Micro complied with relevant U.S. export laws and regulations

    60% confidence
  • Super Micro and certain of its senior executives concealed a massive illegal scheme to sell billions of dollars' worth of advanced AI servers—powered by Nvidia chips subject to U.S. export restrictions—to the People's Republic of China through a Southeast Asian shell entity

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com